drug_type
RELEVANT_DRUG
intervention_type
Biological (monoclonal antibody, anti-CD20)
drug_description
Candidate rituximab biosimilar; chimeric IgG1 anti-CD20 monoclonal antibody that depletes CD20+ B cells via ADCC, CDC, and apoptosis, reducing autoantibody production and B–T cell interactions.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Rituximab
drug_category
CYTOTOXIC ANTIBODY
drug_class
Inhibitor
drug_delivery_route
Intravenous
drug_mechanism_of_action
Chimeric IgG1 anti-CD20 monoclonal antibody that binds CD20 on B lymphocytes and depletes them via ADCC, complement-dependent cytotoxicity, and apoptosis, thereby reducing autoantibody production and B–T cell interactions (plasma cells largely spared).
drug_name
MabionCD20
nct_id_drug_ref
NCT04680962